

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Vitrafy Life Sciences Limited
ABN	48 622 720 254

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brenton (Brent) Owens
Date of last notice	26 November 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Rarla Pty Ltd <Rarla Group A/C> (Director and Beneficiary) Rarla Pty Ltd (Director)
Date of change	15 December 2025
No. of securities held prior to change	Indirect <u>Rarla Pty Ltd</u> <u><Rarla Group A/C></u> 1,918,040 Ordinary Shares <u>Rarla Pty Ltd</u> 123,295 Unlisted Options (Exercisable at \$4.00 per Option, Expiring 30 June 2027) 2,516,000 Unlisted Options (Exercisable at \$1.42 per Option, Expiring 30 June 2029)
Class	Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	275,346
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	N/A (see below)
No. of securities held after change	<p>Direct 275,346 Performance Rights</p> <p>Indirect <u>Rarla Pty Ltd</u> <Rarla Group A/C> 1,918,040 Ordinary Shares</p> <p><u>Rarla Pty Ltd</u> 123,295 Unlisted Options (Exercisable at \$4.00 per Option, Expiring 30 June 2027)</p> <p>2,516,000 Unlisted Options (Exercisable at \$1.42 per Option, Expiring 30 June 2029)</p>
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Grant of 275,346 Performance Rights as approved at Vitrafy Life Sciences Limited's Annual General Meeting on 20 November 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	N/A
Interest after change	N/A

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.